Brodalumab treatment improved clinical signs and symptoms in Phase 2 psoriatic arthritis study

Amgen and AstraZeneca has announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM).